Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J & J Unable to Replace Recalled Drugs Until 2011

By Drug Discovery Trends Editor | June 25, 2010

FORT WASHINGTON, Pa. (AP) – Johnson & Johnson said it will probably not have supplies for some 40 varieties of medications recalled earlier this year until at least 2011, after closing a key manufacturing site.

In late April, J&J’s McNeil unit recalled a variety of children’s and adult over-the-counter medicines due to numerous manufacturing problems at its Fort Washington, Pa. plant.

The recall involved versions of Tylenol, Benadryl, Motrin and other products. Some of the medicines contained excessive ingredient levels while others contained tiny particles of metal.

The Food and Drug Administration is looking into reports of complications with J&J products, though the agency has not directly linked any medical problem to the recalled medicines.

The company said in a release it has not decided when to resume operations at the plant, which was shut down in May.

A spokeswoman declined to provide further information

Products made at the plant generated about $650 million in sales in recent years. The New Brunswick, N.J.-based company reported total sales of $61.9 billion last year.

J&J has long enjoyed a sterling reputation for safety, earned in the 1980s for quickly pulling bottles of Tylenol that had been tainted with cyanide.

J&J had its sales force remove 264,000 Tylenol bottles from store shelves and consumers were urged to return any Tylenol they had for a safe bottle.

Date: June 24, 2010
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE